Silexion Therapeutics Files 8-K
Ticker: SLXNW · Form: 8-K · Filed: Jul 9, 2025 · CIK: 2022416
Sentiment: neutral
Topics: corporate-action, securities-update
Related Tickers: SLXN
TL;DR
Silexion Therapeutics filed an 8-K on 7/9/25 about its shares and warrants.
AI Summary
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on July 9, 2025, reporting on its ordinary shares and warrants. The company, incorporated in the Cayman Islands with principal executive offices in Ramat Gan, Israel, is in the biological products sector.
Why It Matters
This filing provides an update on the company's share structure and warrants, which is important for investors tracking the company's capitalization and potential dilution.
Risk Assessment
Risk Level: low — This is a routine filing providing information about the company's securities and does not indicate any immediate financial distress or significant operational changes.
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Biomotion Sciences (company) — Former company name
- July 9, 2025 (date) — Date of report
- Cayman Islands (jurisdiction) — State of incorporation
- Ramat Gan, Israel (location) — Principal executive offices
FAQ
What is the former name of Silexion Therapeutics Corp?
The former name of Silexion Therapeutics Corp. was Biomotion Sciences, with a date of name change on May 6, 2024.
When was this 8-K report filed?
This 8-K report was filed on July 9, 2025.
Where are Silexion Therapeutics Corp.'s principal executive offices located?
The principal executive offices of Silexion Therapeutics Corp. are located at 12 Abba Hillel Road, Ramat-Gan, Israel, 5250606.
What is the Standard Industrial Classification (SIC) code for Silexion Therapeutics Corp?
The SIC code for Silexion Therapeutics Corp. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
In which jurisdiction was Silexion Therapeutics Corp. incorporated?
Silexion Therapeutics Corp. was incorporated in the Cayman Islands.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 9, 2025 regarding Silexion Therapeutics Corp (SLXNW).